TRIAL DETAIL

Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)

Drug:
Trial Name:
Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Completed
Phase:
3
Start Date 11/01/2011
Age of Trial (yrs) 13.1
Treatment Phase:
All
Drug Category:
none
Strategy:
Targeted therapy
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
CSTI571BDE78T
Sponsor:
Technische Universität München
Patient Contact:
Nikolas von Bubnoff, PD Dr. +49-89-4140 ext 5835 n.bubnoff@lrz.tum.de
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Trial Notes:
* Male or female patients aged >= 18 years
* Histologically confirmed GIST
* Known activating mutation of CKIT or PDGFRA and tissue sample can be provided for central mutation analysis or mutation status unknown and tissue sample can be provided for central mutation analysis at baseline
*At least one GIST lesion that can be measured by CT, PET-CT, or MRI


The current trial aims to evaluate whether tumor DNA carrying mutations for CKIT and PDGFRA can be detected and quantified in the plasma of patients with active GIST, and whether detection can be correlated with the clinical course of disease either under therapy or in progressive disease irrespective of current therapy.

Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years

Trial Links

Trial Results
 

Drug Information
Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST)
 

Trial Sites

Name
Address
City
State
Zip
Country
Munich
D-81675
Germany